Stopping 5-Aminosalicylate Therapy in Patients With Crohn’s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
Clin Gastroenterol Hepatol. 2019 Aug 13;:
Authors: Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF
BACKGROUND & AIMS: Little is known about the effects of discontinuing 5-aminosalycilates (5-ASA) therapy for patients with Crohn’s disease (CD) who initiate therapy with an anti-tumor necrosis factor (anti-TNF) agent. We analyzed data from 2 national population cohorts to compare outcomes of patients with CD already on 5-ASA therapy who started treatment with an anti-TNF agent and then either stopped or continued 5-ASA.
METHODS: The primary outcome was any adverse clinical event, defined as a composite of new corticosteroid use or CD-related hospitalization or surgery. We collected data from the Truven MarketScan health claims database (United States, US) and the Danish health registers. Our analysis included patients with CD who started anti-TNF therapy after at least 90 days of oral 5-ASA therapy. Patients were classified as stopping 5-ASA if therapy was discontinued within 90 days of starting anti-TNF. We performed multivariable Cox regression models controlling for demographics, clinical factors, and healthcare utilization. Adjusted hazard ratios (aHR) with 95% CI values were calculated, comparing stopping 5-ASA with continuing 5-ASA.
RESULTS: A total of 3178 patients with CD were included in our final analysis (2960 in the US and 218 in Denmark). Stopping 5-ASA after initiating anti-TNF therapy was not associated with an increased risk of adverse clinical events in the US cohort (aHR, 0.89; 95% CI, 0.77-1.03; P=.13) or in the Danish cohort (aHR, 1.13; 95% CI, 0.68-1.87; P=.63). Similar results were obtained from sensitivity analyses of concomitant immunomodulator use and duration of 5-ASA treatment before initiation of anti-TNF therapy.
CONCLUSIONS: In a retrospective analysis of 2 national databases, we found that stopping 5-ASA therapy for patients with CD who were starting anti-TNF therapy did not increase their risk of adverse clinical events. These results should be validated in a prospective study.
PMID: 31419574 [PubMed – as supplied by publisher]